 | • レポートコード：MRC2-11QY03886 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は骨髄線維症治療のグローバル市場について調査・分析したレポートです。種類別（輸血、化学療法、アンドロゲン療法）市場規模、用途別（病院、クリニック、骨髄移植センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別骨髄線維症治療の競争状況、市場シェア ・世界の骨髄線維症治療市場：種類別市場規模 2015年-2020年（輸血、化学療法、アンドロゲン療法） ・世界の骨髄線維症治療市場：種類別市場規模予測 2021年-2026年（輸血、化学療法、アンドロゲン療法） ・世界の骨髄線維症治療市場：用途別市場規模 2015年-2020年（病院、クリニック、骨髄移植センター） ・世界の骨髄線維症治療市場：用途別市場規模予測 2021年-2026年（病院、クリニック、骨髄移植センター） ・北米の骨髄線維症治療市場分析：米国、カナダ ・ヨーロッパの骨髄線維症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの骨髄線維症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の骨髄線維症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの骨髄線維症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Incyte、Novartis、Celgene、Mylan Pharmaceuticals、Bristol-Myers Squibb、Eli Lilly、Taro Pharmaceuticals、AllCells、Lonza Group、ATCC ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.
On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.
Market Analysis and Insights: Global Myelofibrosis Treatment Market
The global Myelofibrosis Treatment market size is projected to reach US$ 599.1 million by 2026, from US$ 575.4 million in 2020, at a CAGR of 3.8%% during 2021-2026.
Global Myelofibrosis Treatment Scope and Market Size
Myelofibrosis Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myelofibrosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Incyte
Novartis
Celgene
Mylan Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Taro Pharmaceuticals
AllCells
Lonza Group
ATCC
Market segment by Type, the product can be split into
Blood Transfusion
Chemotherapy
Androgen Therapy
Market segment by Application, split into
Hospitals
Clinics
Bone Marrow Transplant Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Myelofibrosis Treatment Revenue
1.4 Market by Type
1.4.1 Global Myelofibrosis Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Blood Transfusion
1.4.3 Chemotherapy
1.4.4 Androgen Therapy
1.5 Market by Application
1.5.1 Global Myelofibrosis Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Bone Marrow Transplant Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Myelofibrosis Treatment Market Perspective (2015-2026)
2.2 Global Myelofibrosis Treatment Growth Trends by Regions
2.2.1 Myelofibrosis Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myelofibrosis Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Myelofibrosis Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Myelofibrosis Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Myelofibrosis Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Myelofibrosis Treatment Players by Market Size
3.1.1 Global Top Myelofibrosis Treatment Players by Revenue (2015-2020)
3.1.2 Global Myelofibrosis Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Myelofibrosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Myelofibrosis Treatment Market Concentration Ratio
3.2.1 Global Myelofibrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Myelofibrosis Treatment Revenue in 2019
3.3 Myelofibrosis Treatment Key Players Head office and Area Served
3.4 Key Players Myelofibrosis Treatment Product Solution and Service
3.5 Date of Enter into Myelofibrosis Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Myelofibrosis Treatment Historic Market Size by Type (2015-2020)
4.2 Global Myelofibrosis Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Myelofibrosis Treatment Market Size by Application (2015-2020)
5.2 Global Myelofibrosis Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Myelofibrosis Treatment Market Size (2015-2020)
6.2 Myelofibrosis Treatment Key Players in North America (2019-2020)
6.3 North America Myelofibrosis Treatment Market Size by Type (2015-2020)
6.4 North America Myelofibrosis Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Myelofibrosis Treatment Market Size (2015-2020)
7.2 Myelofibrosis Treatment Key Players in Europe (2019-2020)
7.3 Europe Myelofibrosis Treatment Market Size by Type (2015-2020)
7.4 Europe Myelofibrosis Treatment Market Size by Application (2015-2020)
8 China
8.1 China Myelofibrosis Treatment Market Size (2015-2020)
8.2 Myelofibrosis Treatment Key Players in China (2019-2020)
8.3 China Myelofibrosis Treatment Market Size by Type (2015-2020)
8.4 China Myelofibrosis Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Myelofibrosis Treatment Market Size (2015-2020)
9.2 Myelofibrosis Treatment Key Players in Japan (2019-2020)
9.3 Japan Myelofibrosis Treatment Market Size by Type (2015-2020)
9.4 Japan Myelofibrosis Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Myelofibrosis Treatment Market Size (2015-2020)
10.2 Myelofibrosis Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Myelofibrosis Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Myelofibrosis Treatment Market Size by Application (2015-2020)
11 India
11.1 India Myelofibrosis Treatment Market Size (2015-2020)
11.2 Myelofibrosis Treatment Key Players in India (2019-2020)
11.3 India Myelofibrosis Treatment Market Size by Type (2015-2020)
11.4 India Myelofibrosis Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Myelofibrosis Treatment Market Size (2015-2020)
12.2 Myelofibrosis Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Myelofibrosis Treatment Market Size by Type (2015-2020)
12.4 Central & South America Myelofibrosis Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Incyte
13.1.1 Incyte Company Details
13.1.2 Incyte Business Overview
13.1.3 Incyte Myelofibrosis Treatment Introduction
13.1.4 Incyte Revenue in Myelofibrosis Treatment Business (2015-2020))
13.1.5 Incyte Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Myelofibrosis Treatment Introduction
13.2.4 Novartis Revenue in Myelofibrosis Treatment Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Celgene
13.3.1 Celgene Company Details
13.3.2 Celgene Business Overview
13.3.3 Celgene Myelofibrosis Treatment Introduction
13.3.4 Celgene Revenue in Myelofibrosis Treatment Business (2015-2020)
13.3.5 Celgene Recent Development
13.4 Mylan Pharmaceuticals
13.4.1 Mylan Pharmaceuticals Company Details
13.4.2 Mylan Pharmaceuticals Business Overview
13.4.3 Mylan Pharmaceuticals Myelofibrosis Treatment Introduction
13.4.4 Mylan Pharmaceuticals Revenue in Myelofibrosis Treatment Business (2015-2020)
13.4.5 Mylan Pharmaceuticals Recent Development
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Details
13.5.2 Bristol-Myers Squibb Business Overview
13.5.3 Bristol-Myers Squibb Myelofibrosis Treatment Introduction
13.5.4 Bristol-Myers Squibb Revenue in Myelofibrosis Treatment Business (2015-2020)
13.5.5 Bristol-Myers Squibb Recent Development
13.6 Eli Lilly
13.6.1 Eli Lilly Company Details
13.6.2 Eli Lilly Business Overview
13.6.3 Eli Lilly Myelofibrosis Treatment Introduction
13.6.4 Eli Lilly Revenue in Myelofibrosis Treatment Business (2015-2020)
13.6.5 Eli Lilly Recent Development
13.7 Taro Pharmaceuticals
13.7.1 Taro Pharmaceuticals Company Details
13.7.2 Taro Pharmaceuticals Business Overview
13.7.3 Taro Pharmaceuticals Myelofibrosis Treatment Introduction
13.7.4 Taro Pharmaceuticals Revenue in Myelofibrosis Treatment Business (2015-2020)
13.7.5 Taro Pharmaceuticals Recent Development
13.8 AllCells
13.8.1 AllCells Company Details
13.8.2 AllCells Business Overview
13.8.3 AllCells Myelofibrosis Treatment Introduction
13.8.4 AllCells Revenue in Myelofibrosis Treatment Business (2015-2020)
13.8.5 AllCells Recent Development
13.9 Lonza Group
13.9.1 Lonza Group Company Details
13.9.2 Lonza Group Business Overview
13.9.3 Lonza Group Myelofibrosis Treatment Introduction
13.9.4 Lonza Group Revenue in Myelofibrosis Treatment Business (2015-2020)
13.9.5 Lonza Group Recent Development
13.10 ATCC
13.10.1 ATCC Company Details
13.10.2 ATCC Business Overview
13.10.3 ATCC Myelofibrosis Treatment Introduction
13.10.4 ATCC Revenue in Myelofibrosis Treatment Business (2015-2020)
13.10.5 ATCC Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Myelofibrosis Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Myelofibrosis Treatment Revenue
Table 3. Ranking of Global Top Myelofibrosis Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Myelofibrosis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Blood Transfusion
Table 6. Key Players of Chemotherapy
Table 7. Key Players of Androgen Therapy
Table 8. Global Myelofibrosis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Myelofibrosis Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Myelofibrosis Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Myelofibrosis Treatment Market Share by Regions (2015-2020)
Table 12. Global Myelofibrosis Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Myelofibrosis Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Myelofibrosis Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key Myelofibrosis Treatment Players
Table 19. Global Myelofibrosis Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global Myelofibrosis Treatment Market Share by Players (2015-2020)
Table 21. Global Top Myelofibrosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelofibrosis Treatment as of 2019)
Table 22. Global Myelofibrosis Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Myelofibrosis Treatment Product Solution and Service
Table 25. Date of Enter into Myelofibrosis Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Myelofibrosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global Myelofibrosis Treatment Market Size Share by Type (2015-2020)
Table 29. Global Myelofibrosis Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global Myelofibrosis Treatment Market Size Share by Application (2015-2020)
Table 31. Global Myelofibrosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global Myelofibrosis Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players Myelofibrosis Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Myelofibrosis Treatment Market Share (2019-2020)
Table 35. North America Myelofibrosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America Myelofibrosis Treatment Market Share by Type (2015-2020)
Table 37. North America Myelofibrosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America Myelofibrosis Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players Myelofibrosis Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Myelofibrosis Treatment Market Share (2019-2020)
Table 41. Europe Myelofibrosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Myelofibrosis Treatment Market Share by Type (2015-2020)
Table 43. Europe Myelofibrosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Myelofibrosis Treatment Market Share by Application (2015-2020)
Table 45. China Key Players Myelofibrosis Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players Myelofibrosis Treatment Market Share (2019-2020)
Table 47. China Myelofibrosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China Myelofibrosis Treatment Market Share by Type (2015-2020)
Table 49. China Myelofibrosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China Myelofibrosis Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players Myelofibrosis Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Myelofibrosis Treatment Market Share (2019-2020)
Table 53. Japan Myelofibrosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Myelofibrosis Treatment Market Share by Type (2015-2020)
Table 55. Japan Myelofibrosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Myelofibrosis Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Myelofibrosis Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Myelofibrosis Treatment Market Share (2019-2020)
Table 59. Southeast Asia Myelofibrosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Myelofibrosis Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia Myelofibrosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Myelofibrosis Treatment Market Share by Application (2015-2020)
Table 63. India Key Players Myelofibrosis Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players Myelofibrosis Treatment Market Share (2019-2020)
Table 65. India Myelofibrosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India Myelofibrosis Treatment Market Share by Type (2015-2020)
Table 67. India Myelofibrosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India Myelofibrosis Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Myelofibrosis Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Myelofibrosis Treatment Market Share (2019-2020)
Table 71. Central & South America Myelofibrosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Myelofibrosis Treatment Market Share by Type (2015-2020)
Table 73. Central & South America Myelofibrosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Myelofibrosis Treatment Market Share by Application (2015-2020)
Table 75. Incyte Company Details
Table 76. Incyte Business Overview
Table 77. Incyte Product
Table 78. Incyte Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 79. Incyte Recent Development
Table 80. Novartis Company Details
Table 81. Novartis Business Overview
Table 82. Novartis Product
Table 83. Novartis Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 84. Novartis Recent Development
Table 85. Celgene Company Details
Table 86. Celgene Business Overview
Table 87. Celgene Product
Table 88. Celgene Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 89. Celgene Recent Development
Table 90. Mylan Pharmaceuticals Company Details
Table 91. Mylan Pharmaceuticals Business Overview
Table 92. Mylan Pharmaceuticals Product
Table 93. Mylan Pharmaceuticals Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 94. Mylan Pharmaceuticals Recent Development
Table 95. Bristol-Myers Squibb Company Details
Table 96. Bristol-Myers Squibb Business Overview
Table 97. Bristol-Myers Squibb Product
Table 98. Bristol-Myers Squibb Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 99. Bristol-Myers Squibb Recent Development
Table 100. Eli Lilly Company Details
Table 101. Eli Lilly Business Overview
Table 102. Eli Lilly Product
Table 103. Eli Lilly Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 104. Eli Lilly Recent Development
Table 105. Taro Pharmaceuticals Company Details
Table 106. Taro Pharmaceuticals Business Overview
Table 107. Taro Pharmaceuticals Product
Table 108. Taro Pharmaceuticals Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 109. Taro Pharmaceuticals Recent Development
Table 110. AllCells Business Overview
Table 111. AllCells Product
Table 112. AllCells Company Details
Table 113. AllCells Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 114. AllCells Recent Development
Table 115. Lonza Group Company Details
Table 116. Lonza Group Business Overview
Table 117. Lonza Group Product
Table 118. Lonza Group Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 119. Lonza Group Recent Development
Table 120. ATCC Company Details
Table 121. ATCC Business Overview
Table 122. ATCC Product
Table 123. ATCC Revenue in Myelofibrosis Treatment Business (2015-2020) (Million US$)
Table 124. ATCC Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelofibrosis Treatment Market Share by Type: 2020 VS 2026
Figure 2. Blood Transfusion Features
Figure 3. Chemotherapy Features
Figure 4. Androgen Therapy Features
Figure 5. Global Myelofibrosis Treatment Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Bone Marrow Transplant Centers Case Studies
Figure 9. Myelofibrosis Treatment Report Years Considered
Figure 10. Global Myelofibrosis Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Myelofibrosis Treatment Market Share by Regions: 2020 VS 2026
Figure 12. Global Myelofibrosis Treatment Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Myelofibrosis Treatment Market Share by Players in 2019
Figure 15. Global Top Myelofibrosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelofibrosis Treatment as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Myelofibrosis Treatment Revenue in 2019
Figure 17. North America Myelofibrosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Myelofibrosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Myelofibrosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Myelofibrosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Myelofibrosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Myelofibrosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Myelofibrosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
本態性血小板血症骨髄線維症治療の世界市場（～2026年） Market Analysis and Insights: Global Thrombocythaemia Myelofibrosis Treatment Market The global Thrombocythaemia Myelofibrosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Thrombocythaemia Myelofibrosis Tr…- 慢性特発性骨髄線維症の世界市場（～2026年） Idiopathic myelofibrosis is a chronic myelo-proliferative disorder and characterized by abnormal mutation of stem cells. This abnormal mutation of stem cells and excessive production of platelets result in development of fibrous tissues within the bone-marrow. This factor would ultimately negatively…
- 骨髄移植の世界市場（～2026年） Bone marrow transplantation, also referred as hematopoietic stem cell transplantation is the process of replacing diseased or damaged bone marrow or bone marrow stem cells with healthy tissue. Bone marrow is a soft vascular tissue present in the interior of long bones, which is primarily responsible…
- 骨髄移植拒絶反応治療の世界市場（～2026年） Market Analysis and Insights: Global Bone Marrow Transplant Rejection Treatment Market The global Bone Marrow Transplant Rejection Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Bone Marrow Transplant Reject…
- 真性多血症後骨髄線維症（PPV-MF）の世界市場（～2026年） Market Analysis and Insights: Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Post-Polycythemia Vera …